Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience

被引：32

作者：

Stingeni, L. ^{[1
]}

Bianchi, L. ^{[1
,23
]}

Antonelli, E. ^{[1
]}

Caroppo, E. S. ^{[1
]}

Ferrucci, S. M. ^{[2
]}

Ortoncelli, M. ^{[3
]}

Fabbrocini, G. ^{[4
]}

Nettis, E. ^{[5
]}

Schena, D. ^{[6
]}

Napolitano, M. ^{[7
]}

Gola, M. ^{[8
]}

Bonzano, L. ^{[9
]}

Rossi, M. ^{[10
]}

Fortina, A. Belloni ^{[11
]}

Balato, A. ^{[12
]}

Peris, K. ^{[13
]}

Foti, C. ^{[14
]}

Guarneri, F. ^{[15
]}

Romanelli, M. ^{[16
]}

Patruno, C. ^{[17
]}

Savoia, P. ^{[18
]}

Fargnoli, M. C. ^{[19
]}

Russo, F. ^{[20
]}

Errichetti, E. ^{[21
]}

Bianchelli, T. ^{[22
]}

Bianchi, L. ^{[1
,23
]}

Pellacani, G. ^{[24
]}

Feliciani, C. ^{[25
]}

Offidani, A. ^{[26
]}

Corazza, M. ^{[27
]}

Micali, G. ^{[28
]}

Milanesi, N. ^{[29
]}

Malara, G. ^{[30
]}

Chiricozzi, A. ^{[13
]}

Tramontana, M. ^{[1
]}

Hansel, K. ^{[1
]}

机构：

[1] Univ Perugia, Dept Med & Surg, Dermatol Sect, Perugia, Italy

[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

[3] Univ Turin, Dept Med Sci, Div Dermatol, Turin, Italy

[4] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[5] Univ Bari, Dept Emergency & Organ Transplantat, Allergol & Clin Immunol, Bari, Italy

[6] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy

[7] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy

[8] Univ Florence, Dept Hlth Sci, Unit Allergol & Pediat Dermatol, Florence, Italy

[9] Azienda USL IRCCS Reggio Emilia, Dermatol Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

[10] Univ Brescia, Dept Dermatol, ASST Spedali Civili Brescia, Brescia, Italy

[11] Univ Padua, Dept Med DIMED, Unit Dermatol, Padua, Italy

[12] Univ Campania Luigi Vanvitelli, Unit Dermatol, Naples, Italy

[13] Catholic Univ, Inst Dermatol, Rome, Italy

[14] Univ Bari, Dept Biomed Sci & Human Oncol, Sect Dermatol, Bari, Italy

[15] Univ Messina, Dept Clin & Expt Med, Sect Dermatol, Messina, Italy

[16] Univ Pisa, Dermatol Unit, Pisa, Italy

[17] Magna Graecia Univ Catanzaro, Hlth Sci Dept, Sect Dermatol, Catanzaro, Italy

[18] Univ Piemonte Orientale, Dept Hlth Sci, Dermatol Clin, Novara, Italy

[19] Univ LAquila, Dept Biotechnol & Appl Clin Sci, Dermatol, Laquila, Italy

[20] Univ Siena, Dept Clin Surg Med & Neurosci, Sect Dermatol, Siena, Italy

[21] Univ Udine, Inst Dermatol, Dept Med Dame, Udine, Italy

[22] INRCA IRCCS Hosp, Dermatol Unit, Ist Nazl Riposo & Cura Anziani, Ancona, Italy

[23] Univ Tor Vergata, Syst Med Dept, Dermatol Unit, Rome, Italy

[24] Sapienza Univ Rome, Dept Dermatol, Policlin Umberto 1, Rome, Italy

[25] Univ Parma, Dept Clin & Expt Med, Sect Dermatol, Parma, Italy

[26] Polytech Marche Univ, Clin & Mol Sci Dept, Dermatol Clin, Ancona, Italy

[27] Univ Ferrara, Dept Med Sci, Sect Dermatol, Ferrara, Italy

[28] Univ Catania, Dermatol Clin, Catania, Italy

[29] Univ Florence, Dept Surg & Translat Med, Allergol & Occupat Dermatol Unit, Florence, Italy

[30] Grande Osped Metropolitano, Dermatol Unit, Reggio Di Calabria, Italy

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2022年 / 36卷 / 08期

关键词：

QUALITY-OF-LIFE; CHILDREN; ECZEMA; ASTHMA; ASSOCIATION; DERMATOLOGY; POPULATION; PREVALENCE; DIAGNOSIS;

D O I：

10.1111/jdv.18141

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. Objectives A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from >= 12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined. Methods Data of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. Results One hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. Conclusions Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era.

引用

页码：1292 / 1299

页数：8

共 36 条

[1] The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies
Abuabara, K.
Yu, A. M.
Okhovat, J. -P.
Allen, I. E.
Langan, S. M.
[J]. ALLERGY, 2018, 73 (03) : 696 - 704
[2] Epidemiology of atopic dermatitis in adults: Results from an international survey
Barbarot, S.
Auziere, S.
Gadkari, A.
Girolomoni, G.
Puig, L.
Simpson, E. L.
Margolis, D. J.
de Bruin-Weller, M.
Eckert, L.
[J]. ALLERGY, 2018, 73 (06) : 1284 - 1293
[3] Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP)
Calzavara-Pinton, Piergiacomo
Belloni Fortina, Anna
Bonamonte, Domenico
Marseglia, Gian L.
Miraglia Del Giudice, Michele
Musarra, Antonino
Nettis, Eustachio
Neri, Iria
Patruno, Cataldo
Stingeni, Luca
Peris, Ketty
[J]. ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2021, 156 (02) : 184 - 197
[4] Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry
Chiricozzi, Andrea
Talamonti, Marina
De Simone, Clara
Galluzzo, Marco
Gori, Niccolo
Fabbrocini, Gabriella
Marzano, Angelo Valerio
Girolomoni, Giampiero
Offidani, Annamaria
Rossi, Maria Teresa
Bianchi, Luca
Cristaudo, Antonio
Fierro, Maria Teresa
Stingeni, Luca
Pellacani, Giovanni
Argenziano, Giuseppe
Patrizi, Annalisa
Pigatto, Paolo
Romanelli, Marco
Savoia, Paola
Rubegni, Pietro
Foti, Caterina
Milanesi, Nicola
Fortina, Anna Belloni
Bongiorno, Maria Rita
Grieco, Teresa
Di Nuzzo, Sergio
Fargnoli, Maria Concetta
Carugno, Andrea
Motolese, Alberico
Rongioletti, Franco
Amerio, Paolo
Balestri, Riccardo
Potenza, Concetta
Micali, Giuseppe
Patruno, Cataldo
Zalaudek, Iris
Lombardo, Maurizio
Feliciani, Claudio
Di Nardo, Lucia
Guarneri, Fabrizio
Peris, Ketty
[J]. ALLERGY, 2021, 76 (06) : 1813 - 1824
[5] A single-centre real-life experience on effectiveness and safety of dupilumab in adolescents with severe atopic dermatitis in treatment with cyclosporine A
Colonna, C.
Zussino, M.
Ponziani, A.
Gelmetti, C.
Monzani, N. A.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (08) : E533 - E535
[6] Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
Cork, M. J.
Thaci, D.
Eichenfield, L. F.
Arkwright, P. D.
Hultsch, T.
Davis, J. D.
Zhang, Y.
Zhu, X.
Chen, Z.
Li, M.
Ardeleanu, M.
Teper, A.
Akinlade, B.
Gadkari, A.
Eckert, L.
Kamal, M. A.
Ruddy, M.
Graham, N. M. H.
Pirozzi, G.
Stahl, N.
DiCioccio, A. T.
Bansal, A.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) : 85 - 96
[7] Data Resource Center for Child Adolescent Health, 2007, NAT SURV CHILDR HLTH
[8] Atopic dermatitis in schoolchildren and adolescents: a critical review of Italian epidemiological data and systemic treatments
El Hachem, May
Naldi, Luigi
Neri, Iria
Pedone, Maria P.
Fanelli, Francesca
Galeone, Carlotta
[J]. ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2021, 156 (06) : 650 - 658
[9] Dermatology COVID-19 Registries Updates and Future Directions
Freeman, Esther E.
Chamberlin, Grace C.
McMahon, Devon E.
Hruza, George J.
Wall, Dmitri
Meah, Nekma
Sinclair, Rodney
Balogh, Esther A.
Feldman, Steven R.
Lowes, Michelle A.
Marzano, Angelo, V
Naik, Haley B.
Castelo-Soccio, Leslie
Lara-Corrales, Irene
Cordoro, Kelly M.
Mahil, Satveer K.
Griffiths, Christopher E. M.
Smith, Catherine H.
Irvine, Alan D.
Spuls, Phyllis, I
Flohr, Carsten
French, Lars E.
[J]. DERMATOLOGIC CLINICS, 2021, 39 (04) : 575 - 585
[10] Changes in prevalence of asthma and allergies among children and adolescents in Italy: 1994-2002
Galassi, C
De Sario, M
Biggeri, A
Bisanti, L
Chellini, E
Ciccone, G
Petronio, MG
Piffer, S
Sestini, P
Rusconi, F
Viegi, G
Forastiere, F
[J]. PEDIATRICS, 2006, 117 (01) : 34 - 42

← 1 2 3 4 →